An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation

Area of Science:

• Neuroscience
• Immunotherapy
• Alzheimer Disease Therapeutics

Background:

• Alzheimer disease treatment landscape is evolving with new amyloid-targeting immunotherapies.
• Lecanemab shows promise but carries significant patient risks requiring careful management.
• Effective clinical implementation necessitates robust protocols and patient monitoring.

Purpose of the Study:

• To develop and share practical resources for the safe administration of lecanemab.
• To streamline the process of lecanemab infusion and monitoring in a clinical setting.
• To provide a model for other healthcare centers implementing novel Alzheimer therapies.

Main Methods:

• Convened an interprofessional team to address lecanemab infusion logistics.
• Developed patient education materials and clinical documentation templates.
• Established systems and processes for infusion monitoring and management.

Main Results:

• Created a comprehensive set of resources for lecanemab administration.
• Designed adaptable templates and protocols for clinical use.
• Facilitated the safe integration of lecanemab into patient care pathways.

Conclusions:

• The developed resources and processes support the safe and effective implementation of lecanemab.
• Sharing these materials can aid other institutions in managing amyloid-targeting immunotherapies.
• Interprofessional collaboration is key to navigating the complexities of new Alzheimer treatments.